SUPPLEMENTARY MATERIAL

Supplementary Table. Sequence of Events and Procedures.

Visit	Visit 1	Visit 2	Visit 3	Visit 4a	Visit 4b	Visit 5	Phone call
Day	**-50 to -22**	**-21 ± 3**	**-14 ± 3**	**1**	**16 h (+1) from Visit 4a**	**8 ± 3**	**15 ± 3**
PROCEDURE							
General Assessments							
Informed Consent and HIPAA[1]	X						
Demographic Data	X						
Medical and Medication History	x						
Update Medical and Medication History		X	X	X	X	X	X
Allergic Skin Test	X						
Urine Pregnancy Test[2]		X		X		X	
Review Inclusion/Exclusion Criteria	X	X	X	X			
Randomization				X			
AE (nTEAE/TEAE) Assessment	X	X	X	X	X[3]	X[6]	X
Allergen Challenge							
Titration CAC		X					
Confirmation CAC			X				
16 h Duration of Action CAC					X		
15 m Onset of Action CAC						X	
Signs and Symptoms Assessments		X	X	X[4]	X	X	
Relief Drop Instillation[5]		X	X		X	X	
Visual/Systems Exams							
Visual Acuity		X	X	X	X	X[6]	
Slit Lamp Bio microcopy		X	X	X	X	X[6]	
Intraocular Pressure		X				X	
Dilated Fundoscopy		X				X	
Investigational product (IP)							
IP Instillation				X[7]		X[8]	
Drop Comfort & Descriptor Assessment				X			

[1] In the event that a subject has a medical condition, medication/contact lens washout, or needs to speak with the Investigator prior to Visit 1, the subject was given an informed consent form. Medical/medication history, demographics, skin test, and inclusion/exclusion review were performed at the time of informed consent signing prior to Visit 1 but must be confirmed at Visit 1 (with the exception of demographics and skin test).
[2] Urine pregnancy testing was performed, if applicable, for females of childbearing potential.
[3] Performed pre-CAC and post-CAC
[4] Only pre-CAC
[5] Relief medication could be administered to subjects at the end of Visits 2, 3, 4b, and 5, after all evaluations were completed.
[6] Performed pre-CAC and post-CAC as part of the safety exit exam
[7] 16 hour (+1 hour) pre-CAC
[8] 15 (+1) minutes pre-CAC

doi: 10.18176/jiaci.0894